Article
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Clinical cancer research : an official journal of the American Association for Cancer Research - 3 Apr 2023
Patel Sonia A, Nilsson Monique B, Yang Yan, Le Xiuning, Tran Hai T, Elamin Yasir Y, Yu Xiaoxing, Zhang Fahao, Poteete Alissa, Ren Xiaoyang, Shen Li, Wang Jing, Moghaddam Seyed Javad, Cascone Tina, Curran Michael, Gibbons Don L, Heymach John V
Abstract excerpt
PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.